{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:24:46Z","timestamp":1792549486859,"version":"4.5.0"},"reference-count":119,"publisher":"American Society for Clinical Investigation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,19]]},"DOI":"10.1172\/jci142030","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T19:01:33Z","timestamp":1610996493000},"source":"Crossref","is-referenced-by-count":83,"title":["Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes"],"prefix":"10.1172","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6048-7170","authenticated-orcid":false,"given":"Emiliano","family":"Roselli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-3065","authenticated-orcid":false,"given":"Marco L.","family":"Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00384-z"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0247-0"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1183"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.4.619"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813101106"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.210"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19855"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-6-33","article-title":"Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma","volume":"6","author":"Shen","year":"2013","journal-title":"J Hematol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-344275"},{"issue":"5","key":"B22","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0290-5"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1434"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"issue":"224","key":"B28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"Suppl 1","key":"B29","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"crossref","unstructured":"Topp M, et al. Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory large B cell lymphoma. Presented at: 60th American Society of Hematology Annual Meeting; December 1\u20134, 2018; San Diego, CA 2019. https:\/\/doi.org\/10.1182\/blood-2019-126081","DOI":"10.1182\/blood-2019-126081"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14749-3"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.01.010"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3784"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aap9777"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0737-3"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881722"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10565-7"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.01.011"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84813"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-019-0537-3"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936"},{"issue":"Suppl_1","key":"B51","article-title":"Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: results from the US lymphoma CAR-T consortium","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405365"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.142"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1300"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24594"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0231"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2018.10.006"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003293"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2337"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0211"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2008"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2459"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.011"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.08.010"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.021"},{"key":"B75","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-015-0099-4","article-title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","volume":"3","author":"Hammill","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002779"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.010"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2041"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0189"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2016.14"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2013.144"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1421"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010162"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ee6675"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0351"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050674"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1817147116"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.34213"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9114"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092"},{"issue":"4","key":"B95","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/hum.2017.234","article-title":"Nucleofection with plasmid DNA for CRISPR\/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells","volume":"30","author":"Hu","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2281-2"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12321-3"},{"issue":"16","key":"B99","article-title":"Phase 1\/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)","volume":"80","author":"Jacobson","year":"2020","journal-title":"Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.012"},{"key":"B101"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800033"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10940-8"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400044"},{"key":"B106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity","volume":"8","author":"Kueberuwa","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1811"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0376"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701019"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1692-6"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0230"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1831"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050732"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1211"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3050"}],"container-title":["Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jci.org\/articles\/view\/142030\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T17:37:27Z","timestamp":1691084247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jci.org\/articles\/view\/142030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":119,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,19]]},"published-print":{"date-parts":[[2021,1,19]]}},"alternative-id":["10.1172\/JCI142030"],"URL":"https:\/\/doi.org\/10.1172\/jci142030","relation":{},"ISSN":["0021-9738","1558-8238"],"issn-type":[{"value":"0021-9738","type":"print"},{"value":"1558-8238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"article-number":"e142030"}}